Clinical efficacy and pharmacokinetics of antimony in cutaneous leishmaniasis patients treated with sodium stibogluconate

Journal of Clinical Pharmacology

Volumn 50, Issue 11, 2010, Pages 1230-1237

  Zaghloul, Iman Y ^a   Radwan, Mahasen A ^a   Al Jaser, May H ^b   Al Issa, Ramadan ^c  

^a Department of Pharmacotherapy and Translational Research   (Pakistan)

^b Department of Zoology   (India)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

accumulation index; antimony; cutaneous leishmaniasis; pharmacokinetics; sodium stibogluconate

Indexed keywords

ANTIMONY; STIBOGLUCONATE SODIUM;

ADULT; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PLASMA CONCENTRATION-TIME CURVE; SKIN LEISHMANIASIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY EXCRETION;

ADULT; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; HALF-LIFE; HUMANS; INJECTIONS, INTRAMUSCULAR; LEISHMANIASIS, CUTANEOUS; MALE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78449291188     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009347674     Document Type: Article

References (28)

1. World Health Organization (WHO) Report of Expert Committee. The Leishmaniasis. World Health Organization Technical Report Series 701. Geneva, Switzerland: WHO ; 1984.
2. Desjeux P. Leishmaniasis: Public health aspects and control. Clin Derm. 1996 ; 14: 417-423.
3. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004 ; 27: 305-318.
4. Peters W., Al-Zahrani MA The leishmaniases: a public problem in Saudi Arabia. Saudi Med J. 1987 ; 8: 333-343.
5. World Health Organization (WHO). WHO Report of the Workshop of Chemotherapy of Old World Cutaneous Leishmaniasis. TDR/LEISH/CL-JER/83.3. Geneva, Switzerland: WHO ; 1983.
6. Alkhawaja AM, Larbi E., Al-Gindan Y., Abahussein A., Jain S. Treatment of cutaneous leishmaniasis with antimony: intramuscular vs intralesional administration. Ann Trop Med Parasitol. 1997 ; 91: 899-905.
7. Oster CN, Chulay JD, Hendricks LD, et al. American cutaneous leishmaniasis: comparison of three sodium stibogluconate treatment schedules. Am J Trop Med Hyg. 1985 ; 34: 856-860.
8. World Health Organization. Antimonials. Large-scale failure in leishmaniasis "alarming." Trop Dis Res News. 1990 ; 34: 1-7.
9. Navin TR, Arana BA, Arana FE, Berman JD, Chajon JF Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992 ; 165: 528-534.
10. Belazzoug S., Neal RA Failure of meglumine antimonite to cure cutaneous lesions due to Leishmania major in Algeria. Trans R Soc Trop Med Hyg. 1986 ; 80: 670-671.
11. Allen S., Neal RA The in vitro susceptibility of macrophages infected with amastigotes of Leishmania spp. to pentavalent antimonial drugs and other compounds with special relevance to cutaneous isolates. In: Hart DT, ed. Leishmaniasis: The Current Status and New Strategies for Control. Series A Life Sciences. New York, NY: Plenum ; 1989: 711-720.
12. Rowland M., Tozer TN Clinical Pharmacokinetics: Concepts and Application. 2 nd ed. Philadelphia, PA: Lea & Febiger ; 1994.
13. Pamplin CL, Desjardins R., Chulay J., Tramont E., Hendricks L., Canfield C. Pharmacokinetics of antimony during sodium stibogluconate therapy for cutaneous leishmaniasis. Clin Pharmacol Ther. 1981 ; 29: 270-271.
14. Chulay JD, Fleckenstein L., Smith DH Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimonite. Trans R Soc Trop Med Hyg. 1988 ; 82: 69-72.
15. Rees PH, Kager PA, Keating MI, Hockmeyer WT Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet. 1980 ; 2: 226-229.
16. Al-Jaser M., El-Yazigi A., Croft SL Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm Res. 1995 ; 12: 113-116.
17. Cruz A., Rainey M., Herwaldt BL, et al. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J Infect Dis. 2007 ; 195: 602-608.
18. Alnaim L., Abou Alsoud N., Zaghloul I., AL-Jaser M. Effects of fluconazole on the pharmacokinetics and pharmacodynamics of antimony in cutaneous leishmaniasis-infected hamsters. Int J Antimicrob Agents. 2007 ; 29: 728-732.
19. Gibaldi M., Perrier D. Pharmacokinetics. 2 nd ed. New York, NY: Marcel Dekker ; 1982.
20. Croft SL Monitoring drug resistance in leishmaniasis. Trop Med Int Health. 2001 ; 6: 899-905.
21. Berman JD Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis. 1988 ; 10: 560-586.
22. Steck EA The Chemotherapy of Protozoan Disease. Washington, DC: Division of Medicinal Chemistry, Walter Reed Army Institute of Research, Government Printing Office ; 1972.
23. Shortt HE Recent research on Kala-azar in India. Trans R Soc Trop Med Hyg. 1945 ; 39: 13-31.
24. Wijers DJB. A ten years' study of Kala-azar in Tharaka (Meru District, Kenya): II. Relapses. East Afr Med J. 1971 ; 48: 551-558.
25. Al Jaser MH, Radwan MA, Zaghloul IY Pharmacokinetics and tissue distribution of antimonyv after multiple I.M. administration in the hamster. Saudi Pharm J. 2006 ; 14: 52-58.
26. Dorea JG, Merchant-Hamann E., Ryan DE, Holzbecher J. Retention of Sb in skin biopsies of leishmaniasis patients after treatment with N-methyl glucamine antimoniate. Clin Chem. 1990 ; 36: 680-682.
27. Berman JD, Gallalee JF, Gallalee JV Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. Am J Trop Med Hyg. 1988 ; 39: 41-45.
28. Al Jaser M., El-Yazigi A., Kojan M., Croft SL Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis. Antimicrob Agents Chemo. 1995 ; 39: 516-519.